Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC announced disclosures in line with the UK Market Abuse Regulation concerning transactions by individuals in managerial positions. Adrian Morris, the General Counsel, and Tamara Rogers, the Chief Marketing Officer, have both acquired shares under the company’s Share Reward Plan. These transactions were conducted at the London Stock Exchange, involving both Partnership and Matching Shares. Such acquisitions showcase the confidence of Haleon’s leadership in the company’s future prospects and align with its strategic goals to empower key stakeholders.
More about Haleon PLC
Haleon PLC is a global leader in the consumer health industry, focusing on improving everyday health through its diverse product portfolio. The company offers products across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. Well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum reflect Haleon’s commitment to trusted science and innovation.
YTD Price Performance: 3.44%
Average Trading Volume: 22,704,223
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £35.06B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.
